MiR-133a acts as an anti-oncogene in Hepatocellular carcinoma by inhibiting FOSL2 through TGF-β/Smad3 signaling pathway

MiR-133a acts as an anti-oncogene in Hepatocellular carcinoma by inhibiting FOSL2 through TGF-β/Smad3 signaling pathway

Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Biomedicine & Pharmacotherapy - Volume 107, November 2018, Pages 168-176

Lu Sun, Zhixian Guo, Jihong Sun, Jingjing Li, Zihui Dong, Yize Zhang, Jianan Chen, Quancheng Kan, Zujiang Yu,